Sign in
Active, not recruitingNo phase

SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF

Key facts

Who runs it
Center of target therapy
Where
Russia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
30 people enrolled
Started
17 Sept 2025
Ended
2 Feb 2026
Type of study
Observational
Record updated
5 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patient informed consent for the collection and use of data in scientific research
  • Diagnosed chronic hepatitis C (genotype 3)
  • Fibrosis stage F0-F2 according to METAVIR, confirmed by liver biopsy or liver elastography (results of performed studies must be no older than 3 months at the start of antiviral therapy)
  • Signed informed consent
  • Age ≥18 years
  • Antiviral therapy with ravidasvir and sofosbuvir initiated as part of routine clinical practice

Who cannot take part

  • Significant concomitant liver diseases considered relevant by the investigator (hepatitis B, hemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma)
  • If the patient has received other antiviral treatment for hepatitis C within the last 6 months
  • Alcohol or drug dependence that may interfere with adherence to the treatment regimen
  • Presence of other active viral infections (e.g., hepatitis B, HIV)
  • Pregnancy or breastfeeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test). All participants will be receiving the antiviral drugs ravidasvir and sofosbuvir as part of their regular medical care.

Read full original descriptionShow less

Only patients who start this treatment, meet the study's eligibility criteria, and give written consent for their medical data to be used in research will take part. They will be monitored during their routine clinic visits while receiving the two-drug therapy.

After 8 weeks of treatment, researchers will check how many patients have cleared the virus from their blood. Those who achieve this response will continue to be followed for another 4 and 12 weeks after treatment to see if the virus remains undetectable.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective, Single-cohort, Observational Clinical Study Evaluating the Rate of Achieving SVR12 in Patients With Chronic Hepatitis C Genotype 3 With Fibrosis Stage F0-F2 Who Received Ravidasvir + Sofosbuvir Therapy.
Record updated
5 January 2026